12,372 trials
Indolent Non-Hodgkin's Lymphoma · Chronic Lymphocytic Leukemia
Primary: Number of Adverse Events — 298; 302 number of adverse events
Gastric Cancer · Adenocarcinoma
Primary: Overall Survival (OS) — 5.2; 3.8 months — p=0.0473
Acne
Primary: Improvement in Acne — -74; -76; -58 Percent change
Chronic Lymphocytic Leukemia
Primary: Progression-Free Survival — NA; 5.5 months — p=< 0.0001
Lymphoma, Large-Cell, Diffuse
Primary: Progression-free Survival as Assessed by Independent Reviewers — 2.14; 1.81 Months — p=0.333
Prostate Cancer
Primary: Overall Survival — 32.4; 30.2 months — p=<0.0001
Diabetes, Type 1 · Diabetes, Type 2
Primary: Change From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1) by MMRM for TI vs Usual Care — -0.16; -0.12 liters
Diabetes, Type I
Primary: Compare the Mean Change From Baseline to Week 52 in HbA1c — -0.13; -0.37 Percentage
Diabetes Mellitus, Type 2
Primary: Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue — -0.78; -0.70 Percentage of total hemoglobin — p=0.420
Insomnia
Primary: Average Improvement of Latency to Persistent Sleep (LPS) — 45.8; 24.3; 19.6; 23.1 minutes — p=<0.001
Primary Insomnia
Primary: Average Change From Baseline - Latency to Persistent Sleep (LPS) — 45.0; 46.4; 28.3 minutes
Influenza, Human
Primary: Number of Subjects (Unprimed) 6 to <36 Months Age With Local and Systemic Reactions After Any Vaccination for All Seasons, Comparison of Adjuvanted Trivalent Influenza…
Fibromyalgia
Primary: Change in Ventricular Lactate Levels in the Brain — -0.87; 0.32 international units (iu) — p=<0.05
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — 7.70; 7.26; -0.27; -0.80 percent of HbA1c in blood — p=< 0.0001
Major Depressive Disorder
Primary: Change From Baseline in MADRS Total Score at Week 8 — -19.36; -18.16 units on a scale — p=0.199